Effects of rosuvastatin combined with Shuxuetong injection in patients with angina pectoris caused by acute myocardial infarction

Abstract

Objective To evaluate the efficacy and safety of rosuvastatin combined with Shuxuetong injection in the treatment of angina pectoris caused by acute myocardial infarction (AMI). Methods A total of 96 patients with angina pectoris after acute myocardial infarction who were treated in Jiaozhou People’s Hospital from July 2017 to June 2018 were selected and were divided into treatment group (48 cases) and control group (48 cases) according to random number table method. After admission, all patients were given routine treatment. Patients in control group were given rosuvastatin calcium tablets orally. Patients in treatment group were treated with intravenous injection of Shuxuetong on the basis of treatment for control group. The therapeutic effect, levels of platelet activation markers before and after treatment, vascular endothelial growth functional indicators, and incidence of adverse reactions were compared between the two groups. Results The total effective rate of treatment group was significantly higher than that of control group (χ2=12.515, P<0.001). After treatment, levels of platelet activation complex 1(PAC-1), lysosomal granule membrane protein (CD63), P-selectin (CD62p) and lysophosphatidic acid (LPA) in all patients were significantly lower than those before treatment (P all <0.05). After treatment, the levels of CD62p, CD63, PAC-1 and LPA in treatment group were significantly lower than those in control group (P all <0.05). After treatment, levels of nitric oxide (NO), endothelin-1(ET-1) and vascular endothelial growth factor (VEGF) in all patients were significantly lower than those before treatment (P all <0.05). After treatment, levels of NO, ET-1 and VEGF in treatment group were significantly lower than those in control group (P all <0.05). There was no significant difference in the incidence of adverse reactions between the two groups [6.3% (3/48) vs. 12.5% (6/48), χ2=0.490, P=0.483]. Conclusions The use of rosuvastatin combined with Shuxuetong injection in patients with angina pectoris after AMI is safe and effective high safety and good curative effect, by which patients’ platelet function and vascular endothelial growth factor function can be significantly improved, so it is worthy of clinical application. Key words: Rosuvastatin; Shuxuetong injection; Acute myocardial infarction; Angina pectoris